<DOC>
	<DOCNO>NCT02819180</DOCNO>
	<brief_summary>Prospective cohort study evaluate safety immunogenicity Butantan Influenza vaccine ( Fragmented Inactivated ) among healthy adult 18 59 year age elderly old 60 year age .</brief_summary>
	<brief_title>Study Evaluate Safety Immunogenicity Butantan Seasonal Influenza Vaccine - FLU-02-IB</brief_title>
	<detailed_description>Prospective cohort study assess safety one dose theButantan Influenza vaccine ( Fragmented Inactivated ) first 3 day vaccination immunogenicity 21 day vaccination among healthy adult 18 59 year age elderly old 60 year age..</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult , male female age 18 59 Elderly age 60 year complete To available participate study throughout duration ( approximately 21 day ) To medical indication vaccinate influenza To demonstrate intention participate study , document signature studyÂ´s inform consent form . Evidence active neurological , cardiac , pulmonary , hepatic renal disease clinical history and/or physical examination ( except hypertension control among elderly ) Compromised immune system diseases include : HIV , diabetes mellitus , cancer ( except basal cell carcinoma ) autoimmune diseases Behavioral , cognitive psychiatric disease opinion principal investigator representative physician , affect participant ability understand cooperate study protocol requirement Abusive usage alcohol drug past 12 month cause medical , professional family problem , indicate clinical history Known systemic hypersensitivity egg component vaccine History severe adverse reaction previous administration Influenza vaccine within 6 week follow vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Influenza</keyword>
</DOC>